Ниво интерлеукин-6, серумски калпротетин и високе осетљивости Ц-реактивни протеин код повреде слузокоже повезане са Цроновом болестом
Улога серумског калпротетина, високе осетљивости Ц-реактивног протеина и интерлеукин-6 у повреди цревне слузокоже
Sažetak
[Циљ] Да се процени улога калпротетина, високе осетљивости Ц-реактивног протеина и интерлеукин-6 у повреди слузокоже дигестивног тракта код пацијената са Цроновом болестом (ЦД).
[Методи] Изабрано је 52 пацијента дијагностицирана са ЦД. Узорци фекалија пацијената су прикупљени за детекцију калпротетина (ЕЛИСА), а узорци серума су прикупљени за детекцију хс-ЦРП (имунотурбидиметрија) и ИЛ-6 (хемилуминисценција). Сви пацијенти са ЦД прошли су колоноскопију или капсулну ендоскопију. Према модификованом ендоскопском индексу озбиљности ЦД (СЕС-ЦД). Упоређене су промене нивоа калпротетина, хс-ЦРП и ИЛ-6 у две групе, а РОЦ крива је извучена за анализу дијагностичке ефикасности (АУЦ) сваког индекса и ефекта комбиноване детекције на оштећење слузокоже.
[Резултати] Ниво калпротетина и хс-ЦРП у групи повреде слузокоже био је знатно већи од оних у групи зарастања слузокоже. Према РОЦ анализи, АУЦ (0,93, 95% ЦИ: 0,88-0,98), осетљивост (88,5%) и специфичност (89,2%) калпротетин су били највећи када је критична вредност већа од 250 μg/г. АУЦ комбиноване детекције три индикатора (модел логистичке регресије) порастао је на 0,96, што је знатно боље од једног индикатора (П < 0,05).
[Закључак] Ниво интерлеукин-6, серумског калпротетина и високе осетљивости Ц-реактивног протеина значајно су повезани са степеном оштећења слузокоже код пацијената са ЦД. Међу њима, калпротетин има најбољу дијагностичку вредност. Комбинована детекција ова три фактора може значајно побољшати идентификацију оштећења слузокоже током активности ЦД.
Reference
2.Cioffi I, Scialò F, Di Vincenzo O, Gelzo M, Marra M, Testa A, Castiglione F, Vitale M, Pasanisi F, Santarpia L. Serum Interleukin 6, Controlling Nutritional Status (CONUT) Score and Phase Angle in Patients with Crohn's Disease. Nutrients. 2023 Apr 18;15(8):1953. doi: 10.3390/nu15081953. PMID: 37111172; PMCID: PMC10146872.
3.Xiao L, Yang JP, Wang W. [Application of TIGIT combined with interleukin-6 detection in the evaluation of Crohn's disease status]. Zhonghua Yu Fang Yi Xue Za Zhi. 2023 Aug 6;57(8):1253-1258. Chinese. doi: 10.3760/cma.j.cn112150-20230319-00202. PMID: 37574320.
4.Garbers C, Lokau J. Cytokines of the interleukin-6 family as emerging targets in inflammatory bowel disease. Expert Opin Ther Targets. 2024 Jan-Feb;28(1-2):57-65. doi: 10.1080/14728222.2024.2306341. Epub 2024 Jan 23. PMID: 38217849.
5.Shahini A, Shahini A. Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome. J Cell Commun Signal. 2023 Mar;17(1):55-74. doi: 10.1007/s12079-022-00695-x. Epub 2022 Sep 16. PMID: 36112307; PMCID: PMC10030733.
6.Friedberg S, Choi D, Hunold T, Choi NK, Garcia NM, Picker EA, Cohen NA, Cohen RD, Dalal SR, Pekow J, Sakuraba A, Krugliak Cleveland N, Rubin DT. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 Jul;21(7):1913-1923.e2. doi: 10.1016/j.cgh.2023.03.001. Epub 2023 Mar 8. PMID: 36898598; PMCID: PMC11016252.
7.Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitzh H, Wardi J, Zittan E, Ziv-Baran T, Abramas L, Fliss-Isakov N, Raykhel B, Gik TP, Dotan I, Maharshak N. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):49-59. doi: 10.1016/S2468-1253(21)00299-5. Epub 2021 Nov 2. PMID: 34739863.
8.Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Probert CS, Raine T, Saich R, Seward A, Sharpstone D, Smith MA, Subramanian S, Upponi SS, Wiles A, Williams HRT, van den Brink GR, Vermeire S, Jairath V, D'Haens GR, McKinney EF, Lyons PA, Lindsay JO, Kennedy NA, Smith KGC, Parkes M; PROFILE Study Group. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427. doi: 10.1016/S2468-1253(24)00034-7. Epub 2024 Feb 22. PMID: 38402895; PMCID: PMC11001594.
9.Bao C, Wu L, Wang D, Chen L, Jin X, Shi Y, Li G, Zhang J, Zeng X, Chen J, Liu H, Wu H. Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn's disease: A randomized controlled trial. EClinicalMedicine. 2022 Feb 12;45:101300. doi: 10.1016/j.eclinm.2022.101300. PMID: 35198926; PMCID: PMC8850329.
10.Ananthakrishnan AN, Adler J, Chachu KA, Nguyen NH, Siddique SM, Weiss JM, Sultan S, Velayos FS, Cohen BL, Singh S; AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org. AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn's Disease. Gastroenterology. 2023 Dec;165(6):1367-1399. doi: 10.1053/j.gastro.2023.09.029. PMID: 37981354.
11.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
12.Ferrante M, Irving PM, Abreu MT, Axler J, Gao X, Cao Q, Fujii T, Rausch A, Torres J, Neimark E, Song A, Wallace K, Kligys K, Berg S, Liao X, Zhou Q, Kalabic J, Feagan B, Panaccione R. Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial. J Crohns Colitis. 2024 Mar 1;18(3):416-423. doi: 10.1093/ecco-jcc/jjad168. PMID: 37797293; PMCID: PMC10906949.
13.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
14.Akutko K, Iwańczak B. Evaluation of Fecal Calprotectin, Serum C-Reactive Protein, Erythrocyte Sedimentation Rate, Seromucoid and Procalcitonin in the Diagnostics and Monitoring of Crohn's Disease in Children. J Clin Med. 2022 Oct 15;11(20):6086. doi: 10.3390/jcm11206086. PMID: 36294408; PMCID: PMC9604851.
15.Yan W, Meihao W, Zihan S, Lingjie H, Haotian C, Qian C, Lianli S. Correlation Between Crohn's Disease Activity and Serum Selenium Concentration. Clin Ther. 2022 May;44(5):736-743.e3. doi: 10.1016/j.clinthera.2022.03.005. Epub 2022 Apr 1. PMID: 35369995.
16.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
17.Guyard C, de Ponthaud C, Frontali A, Monsinjon M, Giacca M, Panis Y. C-reactive protein monitoring after ileocecal resection and stoma closure reduces length of hospital stay: a prospective case-matched study in 410 patients with Crohn's disease. Tech Coloproctol. 2022 Jun;26(6):443-451. doi: 10.1007/s10151-022-02590-4. Epub 2022 Mar 3. PMID: 35239097.
18.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
19.Takakura WR, Mirocha J, Ovsepyan G, Zaghiyan KN, Syal G, Fleshner P. Magnitude of Preoperative C-Reactive Protein Elevation Is Associated With De Novo Crohn's Disease After Ileal Pouch-Anal Anastomosis in Patients With Severe Colitis. Dis Colon Rectum. 2022 Mar 1;65(3):399-405. doi: 10.1097/DCR.0000000000002148. PMID: 34657077.
20.Zinger A, Choi D, Choi N, Fear E, Fine Z, Cohen RD, Rubin DT. Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn's Disease. Clin Gastroenterol Hepatol. 2024 Oct 24:S1542-3565(24)00968-6. doi: 10.1016/j.cgh.2024.09.027. Epub ahead of print. PMID: 39461462.
21.Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022 Oct;44(10):1336-1355. doi: 10.1016/j.clinthera.2022.08.010. Epub 2022 Sep 21. PMID: 36150926.
22.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
23.Brodersen JB, Kjeldsen J, Juel MA, Knudsen T, Rafaelsen SR, Jensen MD. Changes in Endoscopic Activity and Classification of Lesions With Panenteric Capsule Endoscopy in Patients Treated for Crohn's Disease-A Prospective Blinded Comparison With Ileocolonoscopy, Fecal Calprotectin, and C-Reactive Protein. J Crohns Colitis. 2025 Jan 11;19(1):jjae124. doi: 10.1093/ecco-jcc/jjae124. PMID: 39126260.
24.Takada Y, Kiyohara H, Mikami Y, Taguri M, Sakakibara R, Aoki Y, Nanki K, Kawaguchi T, Yoshimatsu Y, Sugimoto S, Sujino T, Takabayashi K, Hosoe N, Ogata H, Kato M, Iwao Y, Nakamoto N, Kanai T. Leucine-rich alpha-2 glycoprotein in combination with C-reactive protein for predicting endoscopic activity in Crohn's disease: a single-centre, cross-sectional study. Ann Med. 2025 Dec;57(1):2453083. doi: 10.1080/07853890.2025.2453083. Epub 2025 Jan 17. PMID: 39823192; PMCID: PMC11748989.
25.Moskow J, Thurston T, Saleh A, Shah A, Abraham BP, Glassner K. Postoperative Ustekinumab Drug Levels and Disease Activity in Patients with Crohn's Disease. Dig Dis Sci. 2024 Aug;69(8):2944-2954. doi: 10.1007/s10620-024-08471-0. Epub 2024 May 24. PMID: 38789673.
26.Pierre N, Vieujean S, Peyrin-Biroulet L, Meuwis MA, Louis E. Defining Biological Remission in Crohn's Disease: Interest, Challenges and Future Directions. J Crohns Colitis. 2023 Nov 8;17(10):1698-1702. doi: 10.1093/ecco-jcc/jjad086. PMID: 37208498.
27.Muresan S, Slevin M. C-reactive Protein: An Inflammatory Biomarker and a Predictor of Neurodegenerative Disease in Patients With Inflammatory Bowel Disease? Cureus. 2024 Apr 25;16(4):e59009. doi: 10.7759/cureus.59009. PMID: 38665135; PMCID: PMC11045161.
28.Glapa-Nowak A, Szczepanik M, Banaszkiewicz A, Kwiecień J, Szaflarska-Popławska A, Grzybowska-Chlebowczyk U, Osiecki M, Kierkuś J, Dziekiewicz M, Walkowiak J. C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study. Med Sci Monit. 2022 Sep 14;28:e937842. doi: 10.12659/MSM.937842. PMID: 36101481; PMCID: PMC9484282.
29.Santos RCFD, Catapani WR, Takahashi AAR, Waisberg J. C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. Einstein (Sao Paulo). 2022 May 6;20:eAO6500. doi: 10.31744/einstein_journal/2022AO6500. PMID: 35584442; PMCID: PMC9060644.
30.Koifman E, Krasnopolsky M, Ghersin I, Waterman M. Persistently Elevated C-Reactive Protein Levels and Low Body Mass Index Are Associated with a Lack of Improvement in Bone Mineral Density in Crohn's Disease. Nutrients. 2024 Aug 23;16(17):2827. doi: 10.3390/nu16172827. PMID: 39275145; PMCID: PMC11396862.
Sva prava zadržana (c) 2025 Chuanshuo Zhang, Fengning Zhou, Xiandong Cao, Chenyang Qiu, Mingdian Lu, Xin Yu, Pingping Xiang, Bo Yu, Bo Zhou
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.